ulotaront   Click here for help

GtoPdb Ligand ID: 10454

Synonyms: example 129 [WO2011069063A2] [6] | SEP-363856 (parent molecule) | SEP-856 | SEP363856
Compound class: Synthetic organic
Comment: Ulotaront (SEP-363856) is an orally active and brain-penetrant psychotropic agent with a novel mechanism of action. It acts as a trace amine-associated receptor 1 (TAAR1) agonist with additional 5-HT1A receptor agonist activity, and agonism at both of these receptors appears to be required for its clinical effects [2-3]. SEP-363856 is being developed by Sunovion Pharmaceuticals and PsychoGenics, and was granted FDA Breakthrough Therapy Designation as an anti-schizophrenia therapeutic in May 2019. The lack of D2 receptor activity distinguishes SEP-363856 from current antipsychotic medications.
In the Dedic et al. article from 2019 SEP-363856 refers to the hydrochloride salt. We show the parent molecule here. This S enantiomer is more active at TAAR1 compared to the R stereoenantiomer [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 49.5
Molecular weight 183.07
XLogP 0.51
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNCC1OCCc2c1scc2
Isomeric SMILES CNC[C@@H]1OCCc2c1scc2
InChI InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3/t8-/m0/s1
No information available.
Summary of Clinical Use Click here for help
SEP-363856 has progressed to clinical trial as a treatment for schizophrenia [4] and for Parkinson disease-related psychosis [5]. Click here to link to ClinicalTrials.gov's full list of SEP-363856 studies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02969369 A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis Phase 2 Interventional Sunovion
NCT05359081 A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan Phase 3 Interventional Sumitomo Pharma Co., Ltd.
NCT02969382 A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia Phase 2 Interventional Sunovion
NCT02970929 An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia Phase 2 Interventional Sunovion This is an open-label extension study, that recruited patients who had completed participation in the initial 4-week study NCT02969382. 1